Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

China's CDE Slates Highlightll's Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis
CompanyDrug

China’s CDE Slates Highlightll’s Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis

China's Center for Drug Evaluation (CDE) has listed Ginocitinib Tablets (TLL‑018), developed by Hangzhou Highlightll Pharmaceutical Co., Ltd., as a candidate for priority review — a Class 1 innovative oral…

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Ascentage Pharma Secures Additional Indication Approval for Olverembatinib from NMPA

CompanyDrug

Apollomics’ Partner Avistone Wins Conditional Approval for c-Met Inhibitor in China

CompanyDrug

Fosun Pharmaceutical Secures Clinical Trial Approvals for VT-101 in China and the US

CompanyDeals

Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology

CompanyDrug

Pfizer and Astellas Pharma Secure FDA Approval for Xtandi in High-Risk Non-Metastatic Prostate Cancer

CompanyDrug

AstraZeneca Receives FDA Approval for Truqap in HR-Positive, HER2-Negative Breast Cancer

CompanyDrug

Alphamab Oncology’s JSKN003 ADC: Promising Preliminary Data in Advanced Solid Tumors

CompanyDrug

BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC

Show More